Brokerages Issued Rocket Pharmaceuticals Inc (RCKT) Target Price at $27.00

Brokerages Issued Rocket Pharmaceuticals Inc (RCKT) Target Price at $27.00

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $28.50.

A number of analysts have issued reports on the stock. Zacks Investment Research cut shares of Rocket Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, September 12th. LADENBURG THALM/SH SH assumed coverage on shares of Rocket Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $30.00 target price for the company. William Blair assumed coverage on shares of Rocket Pharmaceuticals in a research note on Wednesday, August 8th. They issued a “buy” rating for the company. Finally, ValuEngine upgraded shares of Rocket Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, June 2nd.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Strs Ohio bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at approximately $119,000. Essex Investment Management Co. LLC bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at approximately $306,000. Cobblestone Capital Advisors LLC NY bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at approximately $353,000. State of Wisconsin Investment Board bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at approximately $391,000. Finally, Rhumbline Advisers bought a new position in shares of Rocket Pharmaceuticals in the second quarter valued at approximately $398,000. Hedge funds and other institutional investors own 85.03% of the company’s stock.

NASDAQ RCKT traded down $1.93 during trading on Wednesday, reaching $22.51. The company’s stock had a trading volume of 19,018 shares, compared to its average volume of 145,903. The company has a current ratio of 13.27, a quick ratio of 13.27 and a debt-to-equity ratio of 0.25. Rocket Pharmaceuticals has a 1-year low of $4.88 and a 1-year high of $25.96.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Wednesday, August 8th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.04). analysts anticipate that Rocket Pharmaceuticals will post -1.9 EPS for the current fiscal year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development.

Featured Article: Understanding Price to Earnings Ratio (PE)

Related posts

Leave a Comment